StockMarketWire.com - JP Morgan Cazenove today reaffirms its neutral investment rating on Hikma Pharmaceuticals PLC [LON:HIK] and raised its price target to 1800p (from 1700p).

Story provided by StockMarketWire.com

Broker Forecasts data provided by www.sharesmagazine.co.uk